ArticlePediatric research2026
Measures of neonatal glycemia from blood glucose concentrations and neurodevelopmental outcomes at 2 years.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundNeonatal hypoglycemia is common and associated with adverse neurodevelopmental outcomes, but it is unclear which glycemic measures best explain this association.
methodsBlood glucose concentrations (BGC) from three prospective cohorts of late preterm and term babies born at risk of hypoglycemia, all screened and treated to maintain BGC ≥ 2.6 mmol/L, were used to derive both continuous (maximum, minimum, range, mean, median, standard deviation and variability metrics) and dichotomous glycemic measures (any, severe, recurrent and late hypoglycemic episodes). Generalized linear models adjusted for socioeconomic deprivation, site, primary risk of hypoglycemia and multiple birth related glycemic measures to outcomes at 2 years.
resultsWe analyzed 18,947 BGCs from 2,894 babies. Higher gradient variability was associated with poorer neurodevelopment, but dichotomous indicators were more strongly predictive; e.g. 1 SD increase in gradient variability was associated with -0.9-point adjusted mean Bayley motor score (95% confidence interval -1.4, -0.3), compared to -3.1 (-4.8, -1.5) for severe and -2.1 (-3.6, -0.6) for recurrent hypoglycemia. Associations were similar for Bayley cognitive and language and Brief P global executive composite scores.
conclusionsContinuous glycemic measures derived from intermittent capillary sampling are not stronger predictors of neurodevelopment at 2 years than dichotomous measures, although glycemic variability warrants further investigation. IMPACT: Beyond simple dichotomous classifications (e.g., hypoglycemic or not), little is known about how blood glucose profiles derived from intermittent heel-prick measurements relate to later neurodevelopmental outcomes in infants at risk of neonatal hypoglycemia. Prespecified glycemic measures were related to neurodevelopmental outcomes at 2 years using data from three longitudinal studies of children born at risk of neonatal hypoglycemia. While the dichotomous indicators of severe (<2.0 mmol/L) and recurrent (≥3 episodes) hypoglycemia are most strongly related to neurodevelopmental outcome, measures of glycemic variability also relate to neurodevelopmental risk in infants at risk of neonatal hypoglycemia.
Identifiers
42050117What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.